» Articles » PMID: 9040208

Immunohistochemical Localization of Group II Phospholipase A2 in Colonic Mucosa of Patients with Inflammatory Bowel Disease

Overview
Specialty Gastroenterology
Date 1997 Feb 1
PMID 9040208
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives And Methods: We previously reported the increased contents of group II phospholipase A2 (PLA2) in inflamed colonic mucosa of patients with Crohn's disease and ulcerative colitis (UC). However, the cellular source of the increased group II PLA2 has remained to be clarified. In the present study, we examined immunohistochemical localization of group II PLA2 in inflamed colonic mucosal biopsy samples obtained from eight patients with Crohn's disease, seven with UC, and in normal colonic mucosa of six control subjects without inflammatory bowel disease using a monoclonal antibody raised against human group II PLA2.

Results: and

Conclusions: On immunoblot analysis using the antibody, a single band was detected on each lane containing colonic mucosal homogenates from a control subject, a Crohn's disease patient, or a UC patient at the same position as human group II PLA2 purified from ileal mucosa. The results of immunohistochemistry showed that colonic epithelial cells in inflamed mucosa obtained from all active Crohn's disease patients examined (n = 4) contained immunoreactive group II PLA2. In four of seven patients with active UC, group II PLA2 immunoreactivity was similarly positive. No apparent group II PLA2 immunoreactivity was detected in all colonic mucosal biopsy samples obtained from inactive Crohn's disease patients (n = 4) and control subjects. The present study supports the presence of group II PLA2 in colonic epithelial cells in actively inflamed mucosa of patients with Crohn's disease and UC, which suggests that epithelial cells may serve as the cellular source of increased group II PLA2 content in inflamed colonic mucosa of these patients.

Citing Articles

PLA-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy.

Markovic M, Ben-Shabat S, Nagendra Manda J, Abramov-Harpaz K, Regev C, Miller Y Pharmaceutics. 2022; 14(3).

PMID: 35336048 PMC: 8950246. DOI: 10.3390/pharmaceutics14030675.


Prodrug-Based Targeting Approach for Inflammatory Bowel Diseases Therapy: Mechanistic Study of Phospholipid-Linker-Cyclosporine PLA-Mediated Activation.

Markovic M, Abramov-Harpaz K, Regev C, Ben-Shabat S, Aponick A, Zimmermann E Int J Mol Sci. 2022; 23(5).

PMID: 35269813 PMC: 8910962. DOI: 10.3390/ijms23052673.


Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products.

Markovic M, Ben-Shabat S, Dahan A Pharmaceutics. 2020; 12(11).

PMID: 33137942 PMC: 7692606. DOI: 10.3390/pharmaceutics12111031.


Computational Simulations to Guide Enzyme-Mediated Prodrug Activation.

Markovic M, Ben-Shabat S, Dahan A Int J Mol Sci. 2020; 21(10).

PMID: 32443905 PMC: 7279318. DOI: 10.3390/ijms21103621.


Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics.

Markovic M, Ben-Shabat S, Aponick A, Zimmermann E, Dahan A Int J Mol Sci. 2020; 21(9).

PMID: 32375338 PMC: 7247327. DOI: 10.3390/ijms21093248.